FierceBiotech Mar 30, 2026 Biogen’s litifilimab sparkles in midphase lupus trial, raising hopes for pivotal readout
FierceBiotech Mar 30, 2026 Kardigan hypertension drug tangles biomarker win with blood pressure miss in phase 2 trial
FierceBiotech Mar 30, 2026 Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B
FierceBiotech Mar 27, 2026 'We need to put some bad ideas to bed': Inside Incubate's battles for biotech on Capitol Hill
FierceBiotech Mar 27, 2026 After local tumor approval, Novocure touts positive data in metastatic pancreatic cancer
FierceBiotech Mar 27, 2026 Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions
FierceBiotech Mar 27, 2026 AstraZeneca’s in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars dataset
FierceBiotech Mar 27, 2026 Novartis pens $2B deal for allergy biotech with potential Xolair successor
FierceBiotech Mar 27, 2026 AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops
FierceBiotech Mar 26, 2026 Wave crashes after obesity trial tracks 1% dip in body weight over 6 months
FierceBiotech Mar 26, 2026 Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses